Apple review
As with Biogen, the portfolio has only 1 share (price at the time of writing - $242.66), ~4.75% of the portfolio.
Latest report - here and here.
Apple is the second largest public company in the world by capitalization, more than $1.1 trillion. P/E = 19.3, PEG = 2.3. It is obvious that the years of rapid growth and development are behind the company, net profit over the past 5-6 years has grown on average by a modest 5-7% per year, expected projected values for the next 3-5 years: revenue +7% annually on average, net profit +8.5%. The company's stocks with the maximum weight are included in many indices - S&P500, Nasdaq, and Buffett's portfolio Apple's weight is 29.74%, so for fans of index investing and Buffett - you are welcome 😎
I bought the stock for $158.53 on 01/02/19 and would not buy above $220 at this time. As with Biogen, I will continue to hold it as a stabilization asset, with a share of 3-4% of the portfolio. Below is the traditional graphic -
1⃣ Share price. Here I deliberately took the maximum time period from the very moment of listing on the exchange, and it is the logarithmic graph that is most representative of long time periods. It is obvious that in recent years it has become increasingly difficult for the company to increase profits, which is why shareholder returns are naturally declining.
2⃣ Revenue and profit dynamics, 2020 and beyond - forecast values
3⃣ Earnings per share, 2020 and beyond - forecast values.
Ideas
April 3, 2020